Loading
AVL-102 is an experimental mRNA therapeutic HPV vaccine from Beijing Xunsheng Biomedical Research, in preclinical development for high-grade intraepithelial lesions associated with HPV16/18/52/58.
AVL-102 is a mRNA therapeutic HPV vaccine from Beijing Xunsheng Biomedical Research, with Beijing Anweituo Biomedicine Co., Ltd. as partner. An mRNA vaccine meant to induce cellular immune responses against HPV antigens and clear HPV-infected abnormal cells. Its furthest stage is preclinical development, for high-grade intraepithelial lesions (cervix, anus, vagina, vulva) associated with HPV16/18/52/58 (precancer). No clinical trial naming it is registered on ClinicalTrials.gov. Implied IND approval (默示许可) from China's CDE on 14 August 2026, per company news; no trial start reported. It has not been shown to work in people.
An mRNA vaccine meant to induce cellular immune responses against HPV antigens and clear HPV-infected abnormal cells.
1.AVL-102 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AVL-102" OR ABSTRACT:"AVL-102") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AVL-102, not a curated reading list.
Shares Beijing Xunsheng Biomedical Research and the tag pipeline.
Shares Beijing Xunsheng Biomedical Research and the tag pipeline.
Shares Beijing Xunsheng Biomedical Research and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/